A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression

Martin B. Keller, James P. McCullough, Daniel N. Klein, Bruce Arnow, David L. Dunner, Alan J. Gelenberg, John C. Markowitz, Charles B. Nemeroff, James M. Russell, Michael E. Thase, Madhukar H. Trivedi, John Zajecka, Janice A. Blalock, Frances E. Borian, Darlene N. Jody, Charles DeBattista, Lorrin M. Koran, Alan F. Schatzberg, Jan Fawcett, Robert M A HirschfeldGabor Keitner, Ivan Miller, James H. Kocsis, Susan G. Kornstein, Rachel Manber, Philip T. Ninan, Barbara Rothbaum, A. John Rush, Dina Vivian

Research output: Contribution to journalArticle

992 Citations (Scopus)

Abstract

Background: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients' treatment assignments. Results: Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and the psychotherapy group, as compared with 73 percent in the combined-treatment group (P<0.001 for both comparisons). Among the 519 subjects who completed the study, the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy group, as compared with 85 percent in the combined-treatment group (P<0.001 for both comparisons). The rates of withdrawal were similar in the three groups. Adverse events in the nefazodone group were consistent with the known side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness). Conclusions: Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone. (C) 2000, Massachusetts Medical Society.

Original languageEnglish (US)
Pages (from-to)1462-1470
Number of pages9
JournalNew England Journal of Medicine
Volume342
Issue number20
DOIs
StatePublished - May 18 2000

Fingerprint

Psychotherapy
Depression
Group Psychotherapy
Therapeutics
Medical Societies
Major Depressive Disorder
Dizziness
nefazodone
Drug-Related Side Effects and Adverse Reactions
Nausea
Headache
Mouth
Outpatients

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. / Keller, Martin B.; McCullough, James P.; Klein, Daniel N.; Arnow, Bruce; Dunner, David L.; Gelenberg, Alan J.; Markowitz, John C.; Nemeroff, Charles B.; Russell, James M.; Thase, Michael E.; Trivedi, Madhukar H.; Zajecka, John; Blalock, Janice A.; Borian, Frances E.; Jody, Darlene N.; DeBattista, Charles; Koran, Lorrin M.; Schatzberg, Alan F.; Fawcett, Jan; Hirschfeld, Robert M A; Keitner, Gabor; Miller, Ivan; Kocsis, James H.; Kornstein, Susan G.; Manber, Rachel; Ninan, Philip T.; Rothbaum, Barbara; Rush, A. John; Vivian, Dina.

In: New England Journal of Medicine, Vol. 342, No. 20, 18.05.2000, p. 1462-1470.

Research output: Contribution to journalArticle

Keller, MB, McCullough, JP, Klein, DN, Arnow, B, Dunner, DL, Gelenberg, AJ, Markowitz, JC, Nemeroff, CB, Russell, JM, Thase, ME, Trivedi, MH, Zajecka, J, Blalock, JA, Borian, FE, Jody, DN, DeBattista, C, Koran, LM, Schatzberg, AF, Fawcett, J, Hirschfeld, RMA, Keitner, G, Miller, I, Kocsis, JH, Kornstein, SG, Manber, R, Ninan, PT, Rothbaum, B, Rush, AJ & Vivian, D 2000, 'A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression', New England Journal of Medicine, vol. 342, no. 20, pp. 1462-1470. https://doi.org/10.1056/NEJM200005183422001
Keller, Martin B. ; McCullough, James P. ; Klein, Daniel N. ; Arnow, Bruce ; Dunner, David L. ; Gelenberg, Alan J. ; Markowitz, John C. ; Nemeroff, Charles B. ; Russell, James M. ; Thase, Michael E. ; Trivedi, Madhukar H. ; Zajecka, John ; Blalock, Janice A. ; Borian, Frances E. ; Jody, Darlene N. ; DeBattista, Charles ; Koran, Lorrin M. ; Schatzberg, Alan F. ; Fawcett, Jan ; Hirschfeld, Robert M A ; Keitner, Gabor ; Miller, Ivan ; Kocsis, James H. ; Kornstein, Susan G. ; Manber, Rachel ; Ninan, Philip T. ; Rothbaum, Barbara ; Rush, A. John ; Vivian, Dina. / A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. In: New England Journal of Medicine. 2000 ; Vol. 342, No. 20. pp. 1462-1470.
@article{7249517d705f461b9c6e87f996820933,
title = "A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression",
abstract = "Background: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients' treatment assignments. Results: Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and the psychotherapy group, as compared with 73 percent in the combined-treatment group (P<0.001 for both comparisons). Among the 519 subjects who completed the study, the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy group, as compared with 85 percent in the combined-treatment group (P<0.001 for both comparisons). The rates of withdrawal were similar in the three groups. Adverse events in the nefazodone group were consistent with the known side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness). Conclusions: Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone. (C) 2000, Massachusetts Medical Society.",
author = "Keller, {Martin B.} and McCullough, {James P.} and Klein, {Daniel N.} and Bruce Arnow and Dunner, {David L.} and Gelenberg, {Alan J.} and Markowitz, {John C.} and Nemeroff, {Charles B.} and Russell, {James M.} and Thase, {Michael E.} and Trivedi, {Madhukar H.} and John Zajecka and Blalock, {Janice A.} and Borian, {Frances E.} and Jody, {Darlene N.} and Charles DeBattista and Koran, {Lorrin M.} and Schatzberg, {Alan F.} and Jan Fawcett and Hirschfeld, {Robert M A} and Gabor Keitner and Ivan Miller and Kocsis, {James H.} and Kornstein, {Susan G.} and Rachel Manber and Ninan, {Philip T.} and Barbara Rothbaum and Rush, {A. John} and Dina Vivian",
year = "2000",
month = "5",
day = "18",
doi = "10.1056/NEJM200005183422001",
language = "English (US)",
volume = "342",
pages = "1462--1470",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "20",

}

TY - JOUR

T1 - A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression

AU - Keller, Martin B.

AU - McCullough, James P.

AU - Klein, Daniel N.

AU - Arnow, Bruce

AU - Dunner, David L.

AU - Gelenberg, Alan J.

AU - Markowitz, John C.

AU - Nemeroff, Charles B.

AU - Russell, James M.

AU - Thase, Michael E.

AU - Trivedi, Madhukar H.

AU - Zajecka, John

AU - Blalock, Janice A.

AU - Borian, Frances E.

AU - Jody, Darlene N.

AU - DeBattista, Charles

AU - Koran, Lorrin M.

AU - Schatzberg, Alan F.

AU - Fawcett, Jan

AU - Hirschfeld, Robert M A

AU - Keitner, Gabor

AU - Miller, Ivan

AU - Kocsis, James H.

AU - Kornstein, Susan G.

AU - Manber, Rachel

AU - Ninan, Philip T.

AU - Rothbaum, Barbara

AU - Rush, A. John

AU - Vivian, Dina

PY - 2000/5/18

Y1 - 2000/5/18

N2 - Background: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients' treatment assignments. Results: Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and the psychotherapy group, as compared with 73 percent in the combined-treatment group (P<0.001 for both comparisons). Among the 519 subjects who completed the study, the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy group, as compared with 85 percent in the combined-treatment group (P<0.001 for both comparisons). The rates of withdrawal were similar in the three groups. Adverse events in the nefazodone group were consistent with the known side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness). Conclusions: Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone. (C) 2000, Massachusetts Medical Society.

AB - Background: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients' treatment assignments. Results: Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and the psychotherapy group, as compared with 73 percent in the combined-treatment group (P<0.001 for both comparisons). Among the 519 subjects who completed the study, the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy group, as compared with 85 percent in the combined-treatment group (P<0.001 for both comparisons). The rates of withdrawal were similar in the three groups. Adverse events in the nefazodone group were consistent with the known side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness). Conclusions: Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone. (C) 2000, Massachusetts Medical Society.

UR - http://www.scopus.com/inward/record.url?scp=0034682305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034682305&partnerID=8YFLogxK

U2 - 10.1056/NEJM200005183422001

DO - 10.1056/NEJM200005183422001

M3 - Article

C2 - 10816183

AN - SCOPUS:0034682305

VL - 342

SP - 1462

EP - 1470

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 20

ER -